153 related articles for article (PubMed ID: 7826609)
1. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
[TBL] [Abstract][Full Text] [Related]
2. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.
Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754
[TBL] [Abstract][Full Text] [Related]
3. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L
J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas.
Soini Y; Pääkkö P; Nuorva K; Kamel D; Lane DP; Vähäkangas K
Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):223-8. PubMed ID: 1413488
[TBL] [Abstract][Full Text] [Related]
9. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
10. Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.
Kleinschmidt-DeMasters BK; Hashizumi TL; Sze CI; Lillehei KO; Shroyer AL; Shroyer KR
J Clin Pathol; 1998 Apr; 51(4):284-93. PubMed ID: 9659240
[TBL] [Abstract][Full Text] [Related]
11. Twist predicts poor outcome of patients with astrocytic glioma.
Nordfors K; Haapasalo J; Mäkelä K; Granberg KJ; Nykter M; Korja M; Paavonen T; Haapasalo H; Soini Y
J Clin Pathol; 2015 Nov; 68(11):905-12. PubMed ID: 26163539
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence.
Drach LM; Kammermeier M; Neirich U; Jacobi G; Kornhuber B; Lorenz R; Schlote W
Clin Neuropathol; 1996; 15(2):67-73. PubMed ID: 8925599
[TBL] [Abstract][Full Text] [Related]
13. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
Saito T; Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Hidaka T; Arita K; Kurisu K
J Neurooncol; 2007 Apr; 82(2):193-8. PubMed ID: 17151933
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
15. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
Hilton DA; Penney M; Evans B; Sanders H; Love S
Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
Mastronardi L; Puzzilli F; Guiducci A
Neurosurgery; 1998 Dec; 43(6):1496. PubMed ID: 9848870
[No Abstract] [Full Text] [Related]
18. Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry.
Badhe PB; Chauhan PP; Mehta NK
Indian J Cancer; 2004; 41(4):170-4. PubMed ID: 15659871
[TBL] [Abstract][Full Text] [Related]
19. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors.
Ng HK; Lo SY; Huang DP; Poon WS
Pathology; 1994 Jan; 26(1):1-5. PubMed ID: 8165016
[TBL] [Abstract][Full Text] [Related]
20. p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up.
Vital A; Loiseau H; Kantor G; Daucourt V; Chene G; Cohadon F; Rougier A; Rivel J; Vital C
Pathol Res Pract; 1998; 194(12):831-6. PubMed ID: 9894248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
